Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces its attendance at the United Mitochondrial Disease Foundation’s (UMDF) Mitochondrial Medicine Symposium, taking place virtually on 24-26 June 2021.
The symposium is recognised as one of the world’s preeminent events for mitochondrial disease. It brings together scientific, clinical, industry and patient communities, to explore the latest developments in the field of mitochondrial medicine, including industry advancements, potential treatments, therapies and cutting edge research. Importantly, it gives patients and families the opportunity to meet some of the top clinical mitochondrial specialists from around the world.
Prof. Dr. Jan Smeitink, Chief Executive Officer at Khondrion, said: “We are delighted to be attending this year’s Mitochondrial Medicine Symposium, a key event for all those involved in mitochondrial disease research and the patient community. Despite the unprecedented challenges faced globally over the past year, we applaud the commitment and agility of organisations like the United Mitochondrial Disease Foundation in providing invaluable support for patients. They highlight the strength of this patient community, and we congratulate UMDF on its 25th anniversary.”
For more information on, or to register for, the UMDF Mitochondrial Medicine Symposium visit https://www.umdf.org/symposium/.
– ENDS –
Contacts:
Khondrion BV
Prof. Dr. Jan Smeitink, CEO
E-mail: info@khondrion.com
Tel: +31-24-3617505
Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Melissa Gardiner
E-mail: khondrion@consilium-comms.com
Tel: +44 20 3709 5700
Khondrion is a privately held clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease. Founded by Prof. Jan Smeitink, a world-leader in mitochondrial medicine, the company is advancing its proprietary science through a wholly-owned clinical and preclinical small molecule pipeline of potential medicines.
The company’s in-house discovery engine is using unique live-cell imaging technologies, patient-derived cell lines and predictive cell-based disease models to build a portfolio of promising compounds. Active discovery programmes are underway developing new therapies, biomarkers and new read-out technologies in the field of mitochondrial diseases.
To accelerate the discovery and development of its potential medicines for mitochondrial diseases, Khondrion collaborates with a global clinical and academic network and patient organisations internationally. Khondrion is headquartered in Nijmegen, The Netherlands. For more information visit www.khondrion.com
Mitochondrial disease occurs when mitochondria, found within all cells of the human body and responsible for producing the energy necessary for cells to function, are defective. This can result in a wide range of serious and debilitating illnesses occurring shortly after birth or later in life. Signs and symptoms of these can include: cognitive problems, learning disabilities, blindness, deafness, heart failure, diabetes, fatigue, intolerance to exercise, muscle weakness and gait problems, and stunted growth. Orphan diseases of the oxidative phosphorylation system like Leigh disease, MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) spectrum disorders including MIDD (maternally inherited diabetes and deafness), LHON (Leber’s hereditary optic neuropathy) and other respiratory chain/ oxidative phosphorylation disorders, are all examples of mitochondrial disease.
